Table 6 Comparison of PK parameters in this study with previous published studies
Source | N | Dosage | Status | Cmax (ng/mL) | Tmax (h) | T1/2 (h) | AUC0 − t (h•ng/mL) | |
|---|---|---|---|---|---|---|---|---|
Sulfamethoxazole | Test drug in this study | 26 | 400 mg/80 mg | Fasting | 29,500 ± 5800 | 2.14 ± 0.75 | 8.74 ± 1.15 | 330511.74 ± 44951.68 |
Reference drug in this study | 26 | 400 mg/80 mg | Fasting | 27,100 ± 5620 | 1.83 ± 1.01 | 8.80 ± 1.12 | 323200.10 ± 38368.41 | |
Previous study (Baktar 2011) | 10 | 800 mg/160 mg | Fasting | 58,000 ± 6500 | 1.7 ± 0.7 | 9.4 ± 1.6 | 675,490 ± 100,730 | |
Previous study (UK Public Assessment Report 2015) | - | 800 mg/160 mg | Fasting | 52801.2 ± 8109.56 | - | - | 775342.6 ± 85041.99 | |
Trimethoprim | Test drug in this study | 26 | 400 mg/80 mg | Fasting | 894 ± 208 | 0.96 ± 0.53 | 7.17 ± 1.11 | 8362.34 ± 1999.94 |
Reference drug in this study | 26 | 400 mg/80 mg | Fasting | 863 ± 163 | 1.00 ± 0.65 | 7.18 ± 1.18 | 8120.30 ± 2042.16 | |
Previous study (Baktar 2011) | 10 | 800 mg/160 mg | Fasting | 2060 ± 340 | 2.0 ± 1.2 | 8.2 ± 3.7 | 21,740 ± 4060 | |
Previous study (UK Public Assessment Report 2015) | - | 800 mg/160 mg | Fasting | 1562.2 ± 288.64 | - | - | 22981.3 ± 5550.49 |